Akses terbuka
Jurnal
SINTA 1
Examination of Micro Vascular Density on Metastatic Colorectal Cancer of RAS Mutant-Type as Anti Vegf Therapy Predictor
Folia Medica Indonesiana · Vol. 57 No. 2 (2021) · hlm. 111–111
ISSN 2355-8393, 2599-056X
Terbit 2021-06-01
Penerbit Airlangga University
Bahasa en
Abstrak
According to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Colon Cancer Version 2.2019, mCRC patients with mutant type RAS were treated with anti-VEGF. However, the use of the targeting therapy still had inconsistent results. Neoangiogenesis studies had been used as a basis to assess the prognosis of mCRC. Microvascular density (MVD) had become the morphological gold standard to assess neovascularization in human tumors. This study proved the existence of low microvascular density (MVD) in mCRC patients with mutant type RAS status as a predictor of failure of anti-VEGF therapy. There were 29 patients at Dr. Soetomo Academic Hospital from 2015-2018 who had their RAS status checked and tested for microvascular density (MVD). The results of this study were analyzed using SPSS 23.0. In the Mutant-type of RAS group, this study examined microvascular density (MVD). 11 (73%) research subjects with high MVD scores and 4 (27%) research subjects had low MVD scores. Besides, 27% microvascular density (MVD) was low, in the mutant-type of RAS mCRC patient which could be a predictor factor for the failure of anti-VEGF therapy.
Jaringan kolaborasi para penulis
7 penulis ·
16 tautan kepenulisan bersama
· 9 lintas organisasi
Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.
Universitas Airlangga Universitas Katolik Widya Mandala Surabaya
Organisasi berbeda
Organisasi sama
Afiliasi tidak diketahui
Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.
Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Examination of Micro Vascular Density on Metastatic Colorectal Cancer of RAS Mutant-Type as Anti Vegf Therapy Predictor</dc:title><dc:creator>Heru Sulistyo</dc:creator><dc:creator>Vicky Sumarki Budipramana</dc:creator><dc:subject>metastatic colorectal cancer</dc:subject><dc:subject>RAS mutations</dc:subject><dc:subject>microvessel density</dc:subject><dc:subject>anti-VEGF therapy</dc:subject><dc:subject>treatment failure prediction</dc:subject><dc:subject>tumor angiogenesis</dc:subject><dc:subject>neovascularization</dc:subject><dc:subject>prognostic factors</dc:subject><dc:description xml:lang="en">According to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Colon Cancer Version 2.2019, mCRC patients with mutant type RAS were treated with anti-VEGF. However, the use of the targeting therapy still had inconsistent results. Neoangiogenesis studies had been used as a basis to assess the prognosis of mCRC. Microvascular density (MVD) had become the morphological gold standard to assess neovascularization in human tumors. This study proved the existence of low microvascular density (MVD) in mCRC patients with mutant type RAS status as a predictor of failure of anti-VEGF therapy. There were 29 patients at Dr. Soetomo Academic Hospital from 2015-2018 who had their RAS status checked and tested for microvascular density (MVD). The results of this study were analyzed using SPSS 23.0. In the Mutant-type of RAS group, this study examined microvascular density (MVD). 11 (73%) research subjects with high MVD scores and 4 (27%) research subjects had low MVD scores. Besides, 27% microvascular density (MVD) was low, in the mutant-type of RAS mCRC patient which could be a predictor factor for the failure of anti-VEGF therapy.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2021-06-01</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.20473/fmi.v57i2.18249</dc:identifier><dc:identifier>10.20473/fmi.v57i2.18249</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 57 No 2 (2021); 111-111</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language><dc:relation>https://e-journal.unair.ac.id/FMI/article/download/18249/14930</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc-sa/4.0/</dc:rights></oai_dc:dc>
Sitasi dan pengindeksan
OpenAlex
Terindeks
lewat ID karya OpenAlex (record dari sumber OpenAlex)
2 sitasi
Crossref
Belum diperiksa
Jumlah menurut tiap indeks pada 19 Nov 2026; setiap indeks menghitung sitasi dengan cara berbeda.
OpenAlex juga mencatat karya ini di: crossref, doaj.
Sitasi artikel ini
APA 7
Sulistyo, H., & Budipramana, V. S. (2021). Examination of Micro Vascular Density on Metastatic Colorectal Cancer of RAS Mutant-Type as Anti Vegf Therapy Predictor. Folia Medica Indonesiana, 57(2), 111–111. https://doi.org/10.20473/fmi.v57i2.18249
Salin
IEEE
H. Sulistyo and V. S. Budipramana, “Examination of Micro Vascular Density on Metastatic Colorectal Cancer of RAS Mutant-Type as Anti Vegf Therapy Predictor,” Folia Medica Indonesiana, vol. 57, no. 2, pp. 111–111, 2021, doi: 10.20473/fmi.v57i2.18249.
Salin
Dibuat dari metadata jurnal; periksa nama penulis sebelum dipakai.